Swiss National Bank
RPRX icon

Swiss National Bank’s Royalty Pharma RPRX Stock Holding History

Swiss National Bank’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65M Sell
1,159,800
-31,300
-3% -$1.63M 0.03% 386
2026
Q1 		$57.1M Buy
1,191,100
+65,700
+6% +$2.88M 0.03% 401
2025
Q4 		$43.5M Buy
1,125,400
+32,200
+3% +$1.23M 0.03% 462
2025
Q3 		$38.6M Sell
1,093,200
-22,000
-2% -$796K 0.02% 499
2025
Q2 		$40.2M Buy
1,115,200
+50,100
+5% +$1.66M 0.02% 481
2025
Q1 		$33.2M Sell
1,065,100
-11,000
-1% -$349K 0.02% 506
2024
Q4 		$27.5M Sell
1,076,100
-64,500
-6% -$1.71M 0.02% 564
2024
Q3 		$32.3M Buy
1,140,600
+17,000
+2% +$471K 0.02% 532
2024
Q2 		$29.6M Sell
1,123,600
-13,400
-1% -$371K 0.02% 532
2024
Q1 		$34.5M Sell
1,137,000
-56,200
-5% -$1.66M 0.02% 521
2023
Q4 		$33.5M Sell
1,193,200
-32,300
-3% -$888K 0.02% 526
2023
Q3 		$33.3M Sell
1,225,500
-134,800
-10% -$4M 0.03% 517
2023
Q2 		$41.8M Sell
1,360,300
-40,100
-3% -$1.36M 0.03% 488
2023
Q1 		$50.5M Sell
1,400,400
-20,900
-1% -$775K 0.03% 449
2022
Q4 		$56.2M Sell
1,421,300
-87,910
-6% -$3.67M 0.04% 411
2022
Q3 		$60.6M Buy
1,509,210
+6,700
+0.4% +$286K 0.04% 380
2022
Q2 		$63.2M Buy
1,502,510
+14,200
+1% +$582K 0.04% 396
2022
Q1 		$58M Buy
1,488,310
+189,800
+15% +$7.45M 0.03% 474
2021
Q4 		$51.7M Buy
1,298,510
+599,500
+86% +$23.3M 0.03% 488
2021
Q3 		$25.3M Sell
699,010
-15,500
-2% -$602K 0.02% 628
2021
Q2 		$29.3M Buy
714,510
+42,810
+6% +$1.82M 0.02% 617
2021
Q1 		$29.3M Buy
671,700
+242,200
+56% +$11.5M 0.02% 604
2020
Q4 		$21.5M Buy
+429,500
New +$18.2M 0.02% 642

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss National Bank's RPRX Position: Q2 2026 in Review

Swiss National Bank reduced its Royalty Pharma (RPRX) stake by 2.6% in Q2 2026, selling an estimated $1.63M and leaving 1,159,800 shares worth $65M. The position accounts for 0.03% of the portfolio, ranked #386.

Swiss National Bank first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Swiss National Bank held 1,159,800 shares of Royalty Pharma worth $65M as of Q2 2026.
  • Swiss National Bank sold 31,300 Royalty Pharma shares in Q2 2026, an estimated $1.63M.
  • Royalty Pharma made up 0.03% of Swiss National Bank's portfolio in Q2 2026, its #386 holding.
  • Swiss National Bank first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.